98%
921
2 minutes
20
The genetic associations of TREM2 loss-of-function variants with Alzheimer disease (AD) indicate the protective roles of microglia in AD pathogenesis. Functional deficiencies of TREM2 disrupt microglial clustering around amyloid β (Aβ) plaques, impair their transcriptional response to Aβ, and worsen neuritic dystrophy. However, the molecular mechanism underlying these phenotypes remains unclear. In this study, we investigated the pathological role of another AD risk gene, , encoding a phosphoinositide PI(3,4,5)P phosphatase expressed in microglia. In a -deficient TREM2 loss-of-function mouse model, haplodeficiency restored the association of microglia with Aβ plaques, partially restored plaque compaction, and astrogliosis, and reduced phosphorylated tau dystrophic neurites. Mechanistic analyses suggest that TREM2/TYROBP and INPP5D exert opposing effects on PI(3,4,5)P signaling pathways as well as on phosphoproteins involved in the actin assembly. Our results suggest that INPP5D acts downstream of TREM2/TYROBP to regulate the microglial barrier against Aβ toxicity, thereby modulates Aβ-dependent pathological conversion of tau.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074152 | PMC |
http://dx.doi.org/10.1016/j.isci.2023.106375 | DOI Listing |
J Neurochem
August 2025
Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
The essence of pain involves a multi-system interaction encompassing sensation, emotion, and cognition, with multi-level regulatory mechanisms such as peripheral sensitization, central plasticity, neuroimmune signal crosstalk, and glial cell activation playing critical roles. Among these mechanisms, microglia, as the primary immune effector cells in the central nervous system, contribute significantly to chronic pain by releasing pro-inflammatory factors and modulating synaptic remodeling. Nevertheless, significant gaps remain in our current understanding, including the molecular switch governing the transition from acute to chronic pain, the precise mechanisms regulating microglial phenotypic conversion, and the biological basis of endogenous pain resolution pathways.
View Article and Find Full Text PDFPrevious studies have reported associations between risk of Alzheimer's disease (AD) or dementia and rare coding variants in a number of genes. A two stage strategy was used in which a previously released whole exome sequenced sample was used to prioritise 100 genes showing the strongest evidence for association with AD. These genes were then analysed in a newly released whole genome sequenced sample to identify those which showed statistically significant evidence for rare coding variant association.
View Article and Find Full Text PDFJ Neurogenet
September 2025
UCL Genetics Institute, University College London, London, UK.
Previous studies have reported that rare coding variants in a handful of genes have major effects on risk of Alzheimer's disease (AD). A recent exome wide association study (ExWAS) of dementia in a subset of the UK Biobank cohort implicated a number of genes, including five which were novel. Here we report a similar analysis, carried out on the full cohort of 470,000 exome-sequenced participants.
View Article and Find Full Text PDFTriggering receptor expressed on myeloid cells 2 (TREM2) is a key regulator of microglial function, and its loss-of-function variants are linked to Alzheimer's disease (AD) and neurodegenerative disorders. While TREM2 activation is a promising therapeutic strategy, no small molecule agonists acting via direct TREM2 binding have been reported to date. Here, we describe the discovery of first-in-class, direct small molecule TREM2 agonists identified through DNA-encoded library (DEL) screening.
View Article and Find Full Text PDFBrain Sci
April 2025
Memory and Parkinson's Disease Center, Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, Via La Loggia 1, 90129 Palermo, Italy.
: The activation of microglia and the activity of innate immunity have recently been recognized as part of Parkinson's Disease (PD) pathophysiology. Triggering receptor expressed on myeloid cells 2 (TREM2) is a gene with neuroprotective roles. Its variations are associated with microglial-associated neurodegeneration.
View Article and Find Full Text PDF